Based on the literature review, the current study accesses the systemic inflammation indices and clinical features associated with the TKI treatment-related toxicities and survival outcomes of EGFR-mutated lung adenocarcinoma patients receiving first-line TKI therapy. This evidence concerns the gene EGFR and lung adenocarcinoma.